Defining the toxicity profile of nevirapine and other antiretroviral drugs

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adverse effects; Antiretroviral therapy; Nevirapine; Rash; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; APHTHOUS ULCER; ARTHRALGIA; BLISTER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONJUNCTIVITIS; CROSS REACTION; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EOSINOPHILIA; ERYTHEMA; FACE EDEMA; FATTY LIVER; FETUS DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; MALAISE; MEDICAL DECISION MAKING; MITOCHONDRIAL TOXICITY; MOOD DISORDER; MOUTH LESION; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; NEUROPATHY; PANCREATITIS; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; SERUM SICKNESS; SEX DIFFERENCE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING; VIRUS LOAD;

EXANTHEMA; HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141569901     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00004     Document Type: Conference Paper

References (14)

1. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-391.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
3. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12:1619-1624.
4. Bartlett J, DeMasi R, Quinn J, et al. Meta-analysis of the effectiveness of triple combination therapy in antiretroviral naive HIV-1 patients. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, U.S.A., 2000.
5. Staszewski S, Keiser P, Gathe J, et al. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy naïve adults at 48 weeks. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, U.S.A., 1999.
6. Murphy R, Katlama C, Johnson V, et al. The Atlantic Study. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, U.S.A., 1999.
7. Boehringer Ingelheim International GmbH, Viramuner (nevirapine) tablets. Viramune® (nevirapine) oral suspension. USA Package insert, 2002.
8. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-1092.
9. Montaner J, Gigliotti M, Cahn P, et al. The effects of a short course of prednisone (pred) on the incidence of rash associated with nevirapine (NVP, VIRAMUNE). Presented at the XIII International AIDS Conference, Durban, S. Africa, 2000.
10. Knobel H, Miro JM, De-Miguel V, et al. Efficacy of a short term prednisone regimen in nevirapine associated rash prevention: a double-blind placebo-controlled clinical trial. Results of the GESIDA 09/99 Study. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
11. Beniowski M, Wood R, Gray G, et al. A phase III open-label, randomized, multi-centre study to evaluate the efficacy and tolerability of adding nevirapine (NVP) and/hr Hydroxyurea (HU) to a triple nucleoside-based antiretroviral drug regimen in treatment-naïve HIV-1 infected subjects: 48 week results of the CHARM study [abstract 410]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, U.S.A., 24-28 February 2002.
12. Boehringer Ingelheim International GmbH, Viramune® (nevirapine) tablets. Summary of Product Characteristics, 2000.
13. Clarke S, Harrington P, Condon C, et al. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000;11:336-337.
14. DuPont Pharmaceuticals Company, Sustiva® (efavirenz) capsules. Prescribing Information, U.S.A., 2000.